- Home
- LIXT vs NTHI Comparison
LIXT vs NTHI Comparison
Compare LIXT & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIXT | NTHI |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | 3 | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 114.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LIXT | NTHI |
|---|---|---|
| Price | $7.21 | $4.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 504.5K | 91.7K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $3.71 |
| 52 Week High | $8.38 | $12.99 |
Technical Indicators
Market Signals| Indicator | LIXT | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 42.13 |
| Support Level | $6.21 | $4.17 |
| Resistance Level | $7.64 | $5.78 |
| Average True Range (ATR) | 0.84 | 0.48 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 53.35 | 14.73 |
Price Performance
Historical ComparisonAbout LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.